Top

Infection

Published in:

01-12-2016 | Brief Report

HCV NS3 naturally occurring variants in HIV/HCV coinfected DAA-naïve patients: consideration for HCV genotyping resistance testing

Authors: T. Ruggiero, E. Burdino, A. Calcagno, S. Bonora, L. Boglione, G. Di Perri, V. Ghisetti

Published in: Infection | Issue 6/2016

Abstract

Purpose

Data on the frequency of HCV naturally occurring drug-resistant variants (RAVs) at baseline in HIV/HCV coinfected patients are scarce.

Methods

NS3-HCV RAVs were studied by full-population direct sequencing from plasma specimens of 345 DAA-naïve patients with HCV chronic hepatitis (159 of them with HIV/HCV-coinfection).

Results

NS3 RAVs were identified in 31.5 % of patients, with a significant proportion of HIV/HCV coinfected DAA-naïve patients compared to those with HCV monoinfection (38 vs. 25 % p = 0.0104, OR 1.84; 95 % CI 1.162–2.916).

Conclusions

HCV resistance genotyping test before treatment may be worth in special populations such as HIV/HCV coinfection to optimize patient treatment.

Graham CS, Baden LR, Yu E, Mrus JM, Carnie J, Heeren T, et al. Influence of human immunodeficiency virus infection on the course of hepatitis C virus infection: a meta-analysis. Clin Infect Dis Off Publ Infect Dis Soc Am. 2001;33:562–9.CrossRef

Molina J-M, Orkin C, Iser DM, Zamora F-X, Nelson M, Stephan C, et al. Sofosbuvir plus ribavirin for treatment of hepatitis C virus in patients co-infected with HIV (PHOTON-2): a multicentre, open-label, non-randomised, phase 3 study. Lancet. 2015;385:1098–106.CrossRefPubMed

Sarrazin CJ. The importance of resistance to direct antiviral drugs in HCV infection in clinical practice. J Hepatol. 2016;64:486–504. doi:10.1016/j.jhep.2015.09.011.CrossRefPubMed

Trimoulet P, Belzunce C, Faure M, Wittkop L, Reigadas S, Dupon M, et al. Hepatitis C virus (HCV) protease variability and anti-HCV protease inhibitor resistance in HIV/HCV-coinfected patients. HIV Med. 2011;12:506–9.CrossRefPubMed

Silva T, Cortes Martins H, Coutinho R, Leitão E, Silva R, Pádua E. Molecular characterization of hepatitis C virus for determination of subtypes and detection of resistance mutations to protease inhibitors in a group of intravenous drug users co-infected with HIV. J Med Virol. 2015;87(9):1549–57. doi:10.1002/jmv.24213.CrossRefPubMed

Morsica G, Bagaglio S, Uberti-Foppa C, LA Galli L. Detection of hepatitis C mutants with natural resistance to NS3/4A protease inhibitors in HIV-HCV coinfected individuals treated with antiretroviral therapy. J Acquir Immune Defic Syndr. 2009;51:106–8. doi:10.1097/QAI.0b013e3181a02fda.CrossRefPubMed

Kuntzen T, Timm J, Berical A, Lennon N, Berlin AM, Young K, et al. Naturally occurring dominant resistance mutations to HCV protease and polymerase inhibitors in treatment-naïve patients. Hepatology. 2008;48:1769–78.CrossRefPubMedPubMedCentral

Manns M, Marcellin P, Poordad F, De Araujo ESA, Buti M, Horsmans Y, et al. Simeprevir with pegylated interferon alfa 2a or 2b plus ribavirin in treatment-naive patients with chronic hepatitis C virus genotype 1 infection (QUEST-2): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2014;384:414–26.CrossRefPubMed

Lawitz E, Sulkowski MS, Ghalib R, Rodriguez-Torres M, Younossi ZM, Corregidor A, et al. Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study. Lancet. 2014;384:1756–65. doi:10.1016/S0140-6736(14)61036-9.CrossRefPubMed

10.

Lontok E, Harrington P, Howe A, Kieffer T, Lennerstrand J, Lenz O, et al. Hepatitis C virus drug resistance-associated substitutions: state of the art summary. Hepatology. 2015;62:1623–32.CrossRefPubMed

Title: HCV NS3 naturally occurring variants in HIV/HCV coinfected DAA-naïve patients: consideration for HCV genotyping resistance testing
Authors: T. Ruggiero
E. Burdino
A. Calcagno
S. Bonora
L. Boglione
G. Di Perri
V. Ghisetti
Publication date: 01-12-2016
Publisher: Springer Berlin Heidelberg
Published in: Infection / Issue 6/2016
Print ISSN: 0300-8126
Electronic ISSN: 1439-0973
DOI: https://doi.org/10.1007/s15010-016-0937-4

ACC 2024 Congress Coverage

Heart Failure Video

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

HCV NS3 naturally occurring variants in HIV/HCV coinfected DAA-naïve patients: consideration for HCV genotyping resistance testing

Abstract

Purpose

Methods

Results

Conclusions

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page

At a glance: The ONWARDS insulin icodec trials

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 6/2016

Zika virus disease: a current review of the literature

Nosocomial candidemia in patients admitted to medicine wards compared to other wards: a multicentre study

Carbapenem-resistant Lactobacillus intra-abdominal infection in a renal transplant recipient with a history of probiotic consumption

Measles, mumps, rubella, and varicella seroprevalence in refugees in Germany in 2015

CAND-LO 2014–15 study: changing epidemiology of candidemia in Lombardy (Italy)

Key priorities in the prevention and control of healthcare-associated infection: a survey of European and other international infection prevention experts

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

Incentivised to exercise

New intervention for STEMI-related cardiogenic shock

» View more highlights on the ACC 2024 congress hub page